NEWBORN SCREENING AND LAL-D

Early diagnosis saves lives.

Newborn screening is a fundamental tool for detecting rare diseases such as Lysosomal Acid Lipase Deficiency (LAL-D) from the very first days of life. For babies with Wolman Disease — the most severe form of LAL-D — early detection can be a matter of life or death: without timely intervention, the disease is often fatal before six months of age.

Our organization works to ensure that LAL-D is included in newborn screening programs across Europe. Detecting affected babies early allows families to access life-changing treatment and specialized care from the very beginning.

We are actively involved in the European rare disease community, collaborating with EURORDIS on newborn screening initiatives and contributing to the Screen4Care project.
Through these partnerships, we aim to advance policies, share knowledge, and raise awareness so that every newborn has the opportunity for early diagnosis and a better quality of life.